As CROs and CDMOs expand their role in biopharma development and manufacturing, fast, accurate bioanalytic technologies remain critical to biotherapeutic affordability
Refeyn’s Samux™ benchtop mass photometer enables rapid analysis of adeno-associated virus (AAV) samples.
Oxford, UK – 2 March 2026 – Refeyn, developer of pioneering mass photometry technology, expands its global adoption across contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). To showcase this development, Refeyn has launched a new webpage that highlights how leading CROs and CDMOs are redefining process development and manufacturing workflows with mass photometry, and provides researchers with an interactive tool to locate and partner with these organizations.
Mass photometry’s rapid adoption reflects rising demand for fast, reliable, and cost-effective analytics for protein and mRNA characterization, antibody development, and viral vector analysis. Introduced just eight years ago, the technology is now cited in nearly 1,500 scientific publications and is used by 90% of top biopharma companies. With GMP-compliant software for AAV analytics and recognition from regulatory bodies – including the US Pharmacopeia, China’s NIFDC, and the British Pharmacopeia – mass photometry can be deployed confidently from early development through manufacturing and QC.
Leading CROs and CDMOs use mass photometry to deliver rapid, label-free insights into critical quality attributes – AAV capsid purity (full/empty/partial ratios), mRNA integrity and purity– and emerging antibody modalities. This enables clients to make earlier, better-informed development decisions while reducing sample consumption and turnaround times, tackling analytical challenges that are difficult with traditional methods.
“Adding mass photometry to the analytical panel reduces the overall cost of new therapies by accelerating development and manufacturing,” said Gabriella Kiss, PhD, Director of Market Development at Refeyn. “By working with partners around the world, we’re expanding access to this technology – whether organizations invest in their own instruments or use trusted service providers – ultimately helping shorten the path from discovery to patients.”
CROs and CDMOs can partner with Refeyn to differentiate their analytics and meet growing demand for faster, higher-quality data, while biopharma teams can access mass photometry through the expanding partner network.
To learn more about Refeyn’s CRO/CDMO partnerships and discover how CROs and CDMOs are using mass photometry, visit: https://refeyn.com/cro-cdmo-mass-photometry-services.
Register to meet one of our partners, Franklin Biolabs, in an upcoming webinar, Accelerating GMP Quality Control with Mass Photometry from Development to Release – presented by Ray Zhang, Associate Director, QC Analytics on Thursday, March 26, 2026.
Refeyn Ltd. (www.refeyn.com) specializes in the development, production, and distribution of mass photometry for industry and academia. Enabling accurate mass measurement of single particles in solution, in their native state, and without labels, Refeyn’s products deliver crucial analytics faster and use less sample than conventional methods.
The company’s vision is to accelerate discovery through innovation, empowering the latest scientific breakthroughs in basic research and transforming biotherapeutic development and manufacturing.
Applications of mass photometry include: Characterization of sample purity and heterogeneity, adeno-associated viral (AAV) vector empty/full analysis, assessment of protein oligomerization and interactions, analysis of antibody aggregation and binding, and mRNA sample characterization.
For more information, contact:
Catie Lichten – Scientific Communications Manager, Refeyn
catie.lichten@refeyn.com
